Clinical trial Recruiting at 1 site Observational Ages 21 and up

Testing a wearable device to measure alcohol levels in real-world settings

Official title: Towards a Wearable Alcohol Biosensor: Examining the Accuracy of BAC Estimates From New-Generation Transdermal Technology Using Large-Scale Human Testing and Machine Learning Algorithms

Run by University of Illinois at Urbana-Champaign · NCT05692830 · Data updated 2026-11-12

This study is testing a new wearable device that measures alcohol levels in your body to see how accurately it works in everyday situations.

More Alcohol Drinking trials

Quick facts

Study typeObservational
Ages21 Years and up
SexAll
Enrollment240 (estimated)
SponsorUniversity of Illinois at Urbana-Champaign
Academic / other
Locations1 site (Champaign, Illinois)
StatusRecruiting
StartedOctober 22, 2022
Main results expectedAugust 1, 2026
Study endsSeptember 1, 2027
Registry record updatedAugust 6, 2025
Trial IDNCT05692830 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are adults aged 21 and older who consume alcohol at least twice a week.

Probably not a fit

Patients with psychological or medical conditions contraindicating alcohol consumption or those currently seeking treatment for alcohol use disorder may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study examines the accuracy of a new wearable biosensor that measures transdermal alcohol concentration (TAC) by conducting a combined laboratory and ambulatory assessment over 14 days. Participants will wear the biosensor while also attending three laboratory sessions where they will consume controlled doses of alcohol at varying rates. The goal is to understand the relationship between TAC and breath alcohol concentration (BAC) in diverse real-world contexts. The study utilizes machine learning algorithms to analyze the data collected from participants to improve the accuracy of alcohol level estimations.

Why it matters

Potential benefit: If successful, this study could lead to more accurate and convenient methods for monitoring alcohol consumption, potentially aiding in reducing alcohol-related harm.

How similar studies have gone: While wearable alcohol biosensors are a developing field, this specific approach combining laboratory and real-world assessments is relatively novel and has not been extensively tested in prior studies.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* 21 years or older
* drink alcohol at least 2x weekly

Exclusion Criteria:

* psychological or medical conditions that might contraindicate alcohol-administration
* history of adverse reaction to type and amount of beverage used in the study
* currently seeking treatment for alcohol use disorder
* does not drink alcohol regularly
* taking drugs or medications for which alcohol consumption would be contraindicated
* women who are pregnant or are attempting to become pregnant

Where it's running

  • University of Illinois at Urbana-Champaign
    Champaign, Illinois, United States
    Recruiting

Study contacts

  • Principal investigator: Catharine Fairbairn, PhD — University of Illinois Urbana-Champaign
  • Study coordinator: Catharine Fairbairn, PhD
  • Email: uiucalcohollab@gmail.com
  • Phone: 217-300-5850

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.